Human Fc gamma RIIIA / CD16a (V176) binding Kit (TR-FRET)

• Comprehensive validation - Validated with various antibody subtypes and antibody drugs.
• Simple and fast operation - No complicated washing steps, significantly reducing time.
• High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
• Accurate and reliable results - High sensitivity with minimal matrix effects.
• High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
• Fast completion - Results in just 1 hour.

The Human Fc gamma RIIIA / CD16a (V176) binding Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to measure the interaction between human CD16a (V176) and antibody drug candidates or CD16a (V176) inhibitors. It is designed to facilitate the ADCC functional performance evaluation of antibody drug candidates, high-throughput screening of CD16a (V176) inhibitors within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of antibody drugs to bind to human CD16a (V176).

1. Unopened kit should be stored at 2℃-8℃ upon receiving.

2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

This Human Fc gamma RIIIA / CD16a (V176) binding Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated Fc gamma RIIIA / CD16a (V176) and Europium-chelate labeled streptavidin as the Donor and FA labeled human IgG antibody as the Acceptor.

— When the sample does not contain human Fc gamma RIIIA / CD16a (V176) binding components, the Donor and Acceptor are in close proximity because of the binding of human Fc gamma RIIIA / CD16a (V176) and human IgG antibody. Upon Donor excitation with light of a specific wavelength (337nm), in addition to Donor emission (620nm), non-radiative transfer of energy occurs between Donor and Acceptor, resulting in Acceptor emission (665nm).

— When the sample contains human Fc gamma RIIIA / CD16a (V176) binding components, the components inhibit the binding between the Donor and Acceptor and thereby prevent FRET from occurring.